RxDoctor Payments Data

Francis Constantine, MD

Internal Medicine · New Hartford, NYNPI 1457340432

Payments from drug & device makers

$1,512in general payments, 2019–2025

Across 97 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$364
  • AstraZeneca$233
  • Boehringer Ingelheim$121
  • Novo Nordisk$118
  • Astellas Pharma US Inc$96
  • GSK$94
  • plus $486 from 12 others

What the payments were for

  • Food & beverage$1,47798%
  • Education$352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,512 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$104,354
Medicare patients
305
Services billed
1,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin259$278,355
EliquisApixaban163$158,721
JanuviaSitagliptin Phosphate81$84,332
FarxigaDapagliflozin Propanediol56$77,280
XareltoRivaroxaban63$67,594
OzempicSemaglutide50$58,406
Breo ElliptaFluticasone/Vilanterol43$23,695
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$21,173
MyrbetriqMirabegron21$12,950
Tresiba Flextouch U-100Insulin Degludec18$12,509
EntrestoSacubitril/Valsartan12$12,009
Spiriva HandihalerTiotropium Bromide15$11,610
InvokanaCanagliflozin12$10,845
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$10,282
Lantus SolostarInsulin Glargine,hum.Rec.Anlog76$10,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$121$278,355259 claims
PfizerEliquis$364$158,721163 claims
AstraZenecaFarxiga, Symbicort$233$86,49580 claims
MerckJanuvia$27$84,33281 claims
Johnson & JohnsonXarelto, Invokana$80$78,43975 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Incruse Ellipta$94$60,317104 claims
Novo NordiskOzempic$118$58,40650 claims
Astellas Pharma US IncMyrbetriq$96$12,95021 claims
NovartisEntresto$24$12,00912 claims
AbbVieSynthroid$39$7,766108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New Hartford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →